论文部分内容阅读
目的 探讨心力衰竭患者肿瘤坏死因子 - α( TNF- α)、内皮素 ( ET- 1)的变化及静注胺碘酮对其影响。方法 采用放免法检测 16例心力衰竭患者血浆 TNF- α、ET- 1水平 ,并与 2 0例健康对照组测值进行比较。全数病员均予胺碘酮治疗 ,按一次快速注入 15 0 m g,继后按 6 2 5 μg/ min持续静脉滴注 4 h共 15 0 m g方法给药 ,比较静注胺碘酮对其的影响。结果 心力衰竭患者 ET- 1测值与对照组间存在显著性差异 ( P<0 .0 5 ) ,TNF-α水平无显著性差异 ( P>0 .0 5 ) ;静注胺碘酮 30 0 mg后即刻 TNF-α下降显著 ( P<0 .0 1) ,ET- 1测值亦有下降 ,但统计学处理无显著性差异( P>0 .0 5 )。结论 ET- 1、TNF-α的释放量增加对心力衰竭进程具有促进作用。心力衰竭患者静注胺碘酮为一安全的治疗方法 ,在一定范围内可作为心力衰竭患者抗心律失常的一线紧急用药。
Objective To investigate the changes of tumor necrosis factor-α (TNF-α) and endothelin (ET-1) in patients with heart failure and the effect of intravenous amiodarone on them. Methods The levels of plasma TNF-α and ET-1 in 16 patients with heart failure were measured by radioimmunoassay, and compared with 20 healthy controls. All patients were treated with amiodarone, according to a rapid infusion of 150 mg, followed by continuous infusion of 6 2 5 μg / min 4 h total 15 0 mg method of administration, compared with intravenous amiodarone on its impact . Results ET-1 in patients with heart failure showed significant difference (P <0. 05) and TNF-α levels (P0.05), intravenous amiodarone 30 0 The level of TNF-αdecreased significantly (P <0.01) and the level of ET-1 decreased after treatment, but there was no significant difference between the two groups (P> 0.05). Conclusion The increase of ET-1 and TNF-α release may promote the process of heart failure. In patients with heart failure intravenous amiodarone as a safe treatment, in a certain range can be used as first-line anti-arrhythmic heart failure patients with emergency medication.